Homoharringtonine: A New Treatment Option for Myeloid Leukemia

References

• Powell, R.G., Weisleder, D. and Smith, C.R. (1972) "Anti-tumor alkaloids from Cephalotaxus harringtonia: structure and activity", J. Pharm. Sci. 61, 1227–1230.
   PubMed Web of Science ®Google Scholar
• Huang, M.T. (1975) "Harringtonine, an inhibitor of initiation of protein biosynthesis", Mol. Pharmacol. 11, 511–519.
   PubMedGoogle Scholar
• Grollman, A.P. and Huang, M.T. (1973) "Inhibitors of protein synthesis in eukaryotes: tools in cell research", Fed. Proc. 32, 1673–1680.
   PubMedGoogle Scholar
• Tscherne, J.S. and Pestka, S. (1975) "Inhibition of protein synthesis in intact HeLa cells", Antimicrob. Agents Chemother. 8, 479–487.
   PubMed Web of Science ®Google Scholar
• Fresno, M., Jimenez, A. and Vazquez, D. (1977) "Inhibition of translation in eukaryotic systems by harringtonine", Fur. J. Biochem. 72, 323–330.
   Web of Science ®Google Scholar
• Stall, A.M. and Knopf, P.M. (1978) "The effect of inhibitors of protein synthesis on the reexpression of surface immuno-globulin following antigenic modulation", Cell 14, 33–42.
   PubMed Web of Science ®Google Scholar
• Institute of Material Medica, Chinese Academy of Medical Sciences, Beijing (1979) "Chemical, pharmacological and clinical studies on the antitumor active principle of Cephalotaxus Hainanesis Li", Chin. J. Oncol. 1, 176–181.
   Google Scholar
• Tujebajeva, R.M., Graifer, D.M., Karpova, G.G. and Ajtkhozhina, N.A. (1989) "Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation", FEBS Lett. 257, 254–259.
   PubMed Web of Science ®Google Scholar
• Tujebajeva, R.M., Graifer, D.M., Matasova, N.B., Fedorova, OS., Odintsov, V.B., Ajtkhozhina, N.A. and Karpova, G.G. (1992) "Selective inhibition of the polypeptide chain elongation in eukaryotic cells", Biochim. Biophys. Acta 1129, 177–182.
   PubMed Web of Science ®Google Scholar
• Hobden, A.N. and Cundliffe, E. (1980) "Ribosomal resistance to the 12,13-epoxytrichothecene antibiotics in the producing organism Myrothecium verrucaria", Biochem. J. 190, 765–770.
   PubMed Web of Science ®Google Scholar
• Baez, A. and Vazquez, D. (1978) "Binding of [3H]narciclasine to eukaryotic ribosomes. A study on a structure—activity relationship", Biochim. Biophys. Acta 518, 95–103.
   PubMed Web of Science ®Google Scholar
• Ling, Y.H., Tseng, M.T. and Harty, J.I. (1989) "Effects of homoharringtonine on protein glycosylation in human bladder carcinoma cell T-24", Cancer Res. 49, 76–80.
   PubMed Web of Science ®Google Scholar
• Baaske, D.M. and Heinstein, P. (1977) "Cytotoxicity and cell cycle specificity of homoharringtonine", Antimicrob. Agents Chemother. 12, 298–300.
   PubMed Web of Science ®Google Scholar
• Xu, B. (1981) "The influence of several anticancer agents on cell proliferation, differentiation and the cell cycle of murine erythroleukemia cells", Am. J. Chin. Med. 9, 268–276.
   PubMed Web of Science ®Google Scholar
• Efferth, T., Sauerbrey, A., Halatsch, M.E., Ross, D.D. and Gebhart, E. (2003) "Molecular modes of action of cephalo-taxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines", Naunyn Schmiedebergs Arch. Pharmacol. 367, 56–67.
   PubMed Web of Science ®Google Scholar
• Jiang, T.L., Liu, R.H. and Salmon, S.E. (1983) "Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells", Invest. New Drugs 1, 21–25.
   PubMedGoogle Scholar
• Baguley, B.C., Calveley, S.B., Crowe, K.K., Fray, L.M., O'Rourke, S.A. and Smith, G.P. (1989) "Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice", Fur. J. Cancer Clin. Oncol. 25, 263–271.
   PubMedGoogle Scholar
• Takeda, S., Yajima, N., Kitazato, K. and Unemi, N. (1982) "Antitumor activities of harringtonine and homoharringto-nine, cephalotaxus alkaloids which are active principles from plant by intraperitoneal and oral administration", J. Pharmacobiodyn. 5, 841–847.
   PubMedGoogle Scholar
• Visani, G., Russo, D., Ottaviani, E., Tosi, P., Damiani, D., Michelutti, A., Manfroi, S., Baccarani, M. and Tura, S. (1997) "Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors", Leukemia 11, 624–631.
   PubMed Web of Science ®Google Scholar
• Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y, Honma, Y. and Furukawa, Y. (2001) "In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents", Blood 97, 1999–2007.
   PubMed Web of Science ®Google Scholar
• Scappini, B., Onida, F., Kantarjian, H.M., Dong, L., Verstovsek, S., Keating, M.J. and Beran, M. (2002) "In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells", Cancer 94, 2653–2662.
   PubMed Web of Science ®Google Scholar
• Tipping, A.J., Mahon, F.X., Zafirides, G., Lagarde, V, Goldman, J.M. and Melo, J.V. (2002) "Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs", Leukemia 16, 2349–2357.
   PubMed Web of Science ®Google Scholar
• Cai, Z., Lin, M., Wuchter, C., Ruppert, V, Dorken, B., Ludwig, W.D. and Karawajew, L. (2001) "Involvement of mitochondrial membrane potential in the homoharringto-nine induced apoptosis of leukemic T-cells", Zhonghua Xue Ye Xue Za Zhi 22, 238–240.
   PubMedGoogle Scholar
• Cai, Z., Lin, M., Wuchter, C., Ruppert, V, Dorken, B., Ludwig, W.D. and Karawajew, L. (2001) "Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation", Leukemia 15, 567–574.
   PubMed Web of Science ®Google Scholar
• Meng, X.L. and Lin, M.F. (2003) "Effect of Homoharringto-nine on expression of human telomerase reverse transcrip-tase mRNA in HL-60 Cells", Zhongguo Shi Yan Xue Ye Xue Za Zhi 11, 161–164.
   PubMedGoogle Scholar
• Shi, B. and Han, R. (1999) "Apoptosis inductive effect of homoharringtonine and isoharringtonine on human acute promyelocytic leukemia HL-60 cells", Zhongguo Yi Xue Ke Xue Yuan Xue Bao 21, 356–361.
   PubMedGoogle Scholar
• Li, L., Xia, L.J., Jiang, C. and Han, R. (1994) "Induction of apoptosis by harringtonine and homoharringtonine in HL-60 cells", Yao Xue Xue Bao 29, 667–672.
   PubMedGoogle Scholar
• Jin, W., Huang, Q.S. and Hou, J.M. (2001) "Study on the effect of homoharringtonine on HL-60 and QCY7703 cell lines", Acta Chin. Med. Pharmacol. 29, 44–45.
   Google Scholar
• Xu, L., Liao, Q.K. and Luo, C.H. (1998) "Effects of Fas on homoharringtonine-induced apoptosis in HL-60 cell lines", Chin. J. Pediatr. 36, 607–609.
   Google Scholar
• Xu, L., Liao, Q.K. and Luo, C.H. (1998) "Effects of Bc1-2 and Bax in HL-60 cell line undergo apoptosis induced by homoharringtonine", Shi Yong Er Ke Lin Chuang Za Zhi 13, 249–250.
   Google Scholar
• Shi, J.H., Xu, X.P., Zhang, Z.L., Zhang, J.S., Ge, J.B. and Cheng, W.Y. (2003) "Inhibition of activation of nuclear factor-kappaB enhanced apoptosis of leukemic cells induced by homoharringtonine", Zhonghua Nei Ke Za Zhi 42, 292–296.
   PubMedGoogle Scholar
• Wang, H., Guo, Z. and Ji, S. (2000) "Homoharringtonine induces apoptosis of K562 cells through inhibition of P210(bcr/abl)", Zhongguo Shi Yan Xue Ye Xue Za Zhi 8, 287–289.
   PubMedGoogle Scholar
• Wang, Y., Sun, G.L. and Wu, W.L. (2001) "Preliminary study on the effect of Bc1-2 family in apoptosis induced by homoharringtonine on K562", Acta Universitatis Medicinalis Secondae Shanghai 21, 289–291.
   Google Scholar
• Wang, Y., Sun, G.L. and Wu, W.L. (2001) "Experiment study of apoptosis and differentiation on K562 and CML cell induced by homoharringtonineage", Shanghai Med. J. 24, 166–168.
   Google Scholar
• Shi, J.H., Xu, X.P. and Yang, X. (1998) "Apoptosis induced by homoharringtonine in K562 cells", Chin. J. Oncol. 8,205–207.
   Google Scholar
• Xu, Q., Tang, J.Y. and Wu, G. (2001) "Correlation of apoptosis and N-myc gene espression in neuroblastoma induced by arsenic trioxide and homoharringtonine", Ai Zheng 20, 239–244.
   Google Scholar
• Tang, X.D., Zhou, K.Y. and Ding, H. (2002) "Changes of the Caspase-6 and -8 activity during the homoharringtonine-induced apoptosis in nasopharyngeal carcinoma cell CNE-2Z", Tumori 22, 279–281.
   Google Scholar
• Tang, X.D., Zhou, K.Y. and Zhou, Q.F. (2003) "Effects of homoharringtonine on inhibition of proliferation and induction of apoptosis of nasopharyngeal carcinoma cells CNE-2Z", Zhongguo Yao Li Xue Za Zhi 19, 63–66.
   Google Scholar
• Xiang, Q., Wang, C.Y. and Xu, X.L. (1997) "Homoharringto-nine-induced retinoblastoma programmed cell death", Chin. J. Ocul. Fudus. Dis. 13, 70–72.
   Google Scholar
• Chen, Z.X., Wang, W. and Wu, W.L. (1989) "Heterogenous response of primary cultured bone marrow cells of patients with different varieties of leukemia to differentiation inducers", Chin. Med. J. (Engl) 102, 174–182.
   PubMed Web of Science ®Google Scholar
• Zhou, J.Y., Chen, D.L., Shen, Z.S. and Koeffler, H.P. (1990) "Effect of homoharringtonine on proliferation and differen-tiation of human leukemic cells in vitro", Cancer Res. 50, 2031–2035.
   PubMed Web of Science ®Google Scholar
• Lu, K., Savaraj, N., Feun, L.G., Guo, Z.G., Umsawasdi, T. and Loo, T.L. (1988) "Pharmacokinetics of homoharringtonine in dogs", Cancer Chemot her. Pharmacol. 21, 139–142.
   PubMed Web of Science ®Google Scholar
• Cui, Y.Y. and Wang, M.Z. (1991) "The metabolism of homoharringtonine by liver microsomes of rats and rabbits", Yao Xue Xue Bao 26, 274–282.
   PubMedGoogle Scholar
• Ni, D., Ho, D.H., Vijjeswarapu, M., Felix, E., Rhea, P.R. and Newman, R.A. (2003) "Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia", J. Exp. Ther. Oncol. 3, 47–52.
   PubMedGoogle Scholar
• Ji, X.J., Liu, Y, Lin, H. and Liu, Z.M. (1982) "Metabolism of homoharringtonine in rats and mice", Yao Xue Xue Bao 17, 881–888.
   PubMedGoogle Scholar
• Savaraj, N., Lu, K., Dimery, I., Feun, L.G., Burgess, M., Keating, M. and Loo, T.L. (1986) "Clinical pharmacology of homoharringtonine", Cancer Treat. Rep. 70, 1403–1409.
   PubMedGoogle Scholar
• Xu, C.X. and Han, R. (1989) "Cytocidal action of homoharringtonine on L1210 cells in vitro", Zhongguo Yao Li Xue Bao 10, 546–560.
   Google Scholar
• Fountzilas, G., Lim, L.O. and Yunis, A.A. (1988) "The inhibitory effects of teniposide and homoharringtonine on the growth of pancreatic carcinoma cells in vitro", Anticancer Res. 8, 343–348.
   PubMed Web of Science ®Google Scholar
• Gupta, R.S., Murray, W. and Gupta, R. (1988) "Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line", Br. J. Cancer 58, 441–447.
   PubMed Web of Science ®Google Scholar
• Zhou, D.C., Ramond, S., Viguie, F., Faussat, A.M., Zittoun, R. and Marie, J.P. (1996) "Sequential emer-gence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines", Int. J. Cancer 65, 365–371.
   PubMed Web of Science ®Google Scholar
• He, Q.Y., Zhou, W.D., Ji, L., Zhang, H.Q., He, N.G. and Xue, S.B. (1996) "Characteristics of harringtonine-resistant human leukemia HL60 cell", Zhongguo Yao Li Xue Bao 17, 463–469.
   PubMed Web of Science ®Google Scholar
• Han, J.L., Yan, W.W. and Qian, Q.J (1994) "2 homoharring-tonine resistant leukemic cell lines (K562 HHT and L1210 HHT): establishment, characterization and mechanisms of action Zhonghua Yi Xue Za Zhi, 74 424–430, 456.
   PubMedGoogle Scholar
• Tebbi, C.K., Chervinsky, D. and Baker, R.M. (1991) "Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporine A and dipyridamole", J. Cell. Physiol. 148, 464–471.
   PubMed Web of Science ®Google Scholar
• Chervinsky, D.S., Brecher, M.L., Baker, R.M., Hoelcle, M.J. and Tebbi, C.K. (1993) "Reversal of C1300 murine neuroblastoma multidrug resistance by cremophorEL, a solvent for cyclosporin A", Cancer Biother. 8, 67–75.
   PubMedGoogle Scholar
• Russo, D., Michelutti, A., Melli, C., Damiani, D., Michieli, M.G., Candoni, A., Zhou, D.C., Marie, J.P., Zittoun, R. and Baccarani, M. (1995) "MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine", Leukemia 9, 513–518.
   PubMed Web of Science ®Google Scholar
• Wilkoff, L.J., Dulmadge, E.A., Vasanthakumar, G. and Donahue, J.P. (1993) "Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine", Cancer Chemother. Pharmacol. 33, 149–153.
   PubMed Web of Science ®Google Scholar
• Li, Y.F. (1990) "Clinical evaluation on the therapeutic efficacy of HA and HHA on acute nonlymphocytic leukemia", Chin. J. Gin. Oncol. 17, 240–243.
   Google Scholar
• C. fortunei Hook. f. Research Cooperative Team (1975) "A preliminary clinical evaluation of acute leukemia treated with Cephalotaxus fortunei Hook f. alkaloids", J. Chin. Acad. 55, 712–718.
   Google Scholar
• Shanghai Leukemia Research Cooperative Group (1983) "Clinical study of Cephalotaxin esters in the treatment of acute nonlymphocytic leukemia", Shanghai Med. J. 6, 319–324.
   Google Scholar
• Fujian province leukemia research cooperative group (1978) "Homoharringtonine and harringtonine in acute non-lymphocytic leukemia: clinical obervation of 40 cases", Chin. J. Intern. Med. 17, 162–164.
   Google Scholar
• Hou, C.Z. and Zhang, Z.Y. (1981) "Intrathecal injection of harringtonine and homoharringtonine in treating central nervous system leukemia—clinical analysis in 26 cases", J. Chin. Acad. 61, 530–532.
   Google Scholar
• Low Dose Homoharringtonine Therapy East China cooperative group (1988) "Preliminary observation of low dose homoharringtonine in treatment of acute nonlympho-cytic leukemia in 48 cases", Chin. J. Hematol. 9, 499–500.
   Google Scholar
• Neidhart, J.A., Young, D.C., Derocher, D. and Metz, E.N. (1983) "Phase I trial of homoharringtonine", Cancer Treat. Rep. 67, 801–804.
   PubMedGoogle Scholar
• Coonley, C.J., Warrell, R.P. and Young, C.W. (1983) "Phase I trial of homoharringtonine administered as a 5-day continuous infusion", Cancer Treat. Rep. 67, 693–698.
   PubMedGoogle Scholar
• Legha, S.S., Keating, M., Picket, S., Ajani, J.A., Ewer, M. and Bodey, G.P. (1984) "Phase I clinical investigation of homoharringtonine", Cancer Treat. Rep. 68, 1085–1091.
   PubMedGoogle Scholar
• Stewart, J.A. and Krakoff, I.H. (1985) "Homoharringtonine: a phase I evaluation", Invest. New Drugs 3, 279–286.
   PubMed Web of Science ®Google Scholar
• Neidhart, J.A., Young, D.C., Kraut, E., Howinstein, B. and Metz, E.N. (1986) "Phase I trial of homoharringtonine administered by prolonged continuous infusion", Cancer Res. 46, 967–975.
   PubMed Web of Science ®Google Scholar
• Tan, C.T., Luks, E., Bacha, D.M., Steinherz, P., Steinherz, L. and Mondora, A. (1987) "Phase I trial of homoharringtonine in children with refractory leukemia", Cancer Treat. Rep. 71, 1245–1252.
   PubMedGoogle Scholar
• Warren, RE, Coonley, C.J. and Gee, T.S. (1985) "Homo-harringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia", J. Clin. Oncol. 3, 617–621.
   PubMed Web of Science ®Google Scholar
• Stewart, J.A., Cassileth, P.A., Bennett, J.M. and O'Connell, M.J. (1988) "Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study", Am. J. Clin. Oncol. 11, 627–635.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H.M., Keating, M.J., Walters, R.S., Koller, C.A., McCredie, K.B. and Freireich, E.J. (1989) "Phase II study of low-dose continuous infusion homoharringtonine in refrac-tory acute myelogenous leukemia", Cancer 63, 813–819.
   PubMed Web of Science ®Google Scholar
• Feldman, E., Arlin, Z., Ahmed, T., Mittelman, A., Puccio, C., Chun, H., Cook, P. and Baskind, P. (1992) "Homo-arringtonine is safe and effective for patients with acute myelogenous leukemia", Leukemia 6, 1185–1192.
   PubMed Web of Science ®Google Scholar
• Bell, B.A., Chang, M.N. and Weinstein, H.J. (2001) "A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study", Med. Pediatr. Oncol. 37, 103–109.
   PubMedGoogle Scholar
• Lu, J.X., Yan, P.H. and Ke, C.J. (1979) "A preliminary observation of the therapeutic effect of Cephalotaxine esters combined with traditional Chinese medicine in the treat-ment of 19 cases of Nonlymphocytic leukemia", Acta. Acad. Med. Primae. Shanghai 6, 249–254.
   Google Scholar
• Hematological Research Section of Suzhou Medical Collage (1981) "Analysis of 51 cases of acute nonlympho-cytic leukemia treated with combined programme of Chinese traditional medical and HOAP", Chin. J. Intern. Med. 20, 205–207.
   PubMedGoogle Scholar
• Lu, L.H., Chen, J.X. and Liang, Y.Y. (1981) "Clinical observation of the therapeutic effect in 19 cases of acute nonlymphocytic leukemia with combined Chinese tradi-tional and western medicine", Chin. J. Intern. Med. 20, 732–734.
   PubMedGoogle Scholar
• Li, Y.H., Kuo, S.F. and Zhou, F.Y. (1981) "A report of Cephalotaxine esters in the combined treatment in 25 cases of acute nonlymphocytic leukemia", Chin. J. Pediatr. 19, 231–233.
   Google Scholar
• Hematological Group, Department of Internal Medicine, the third Affiliated Hospital, Beijing Medical Collage (1980) "The "HHOAP" regimen in the treatment of acute Nonlymphocytic leukemia. Clinical observation of 21 cases", J. Beijing Med. Collage 12, 184–186.
   Google Scholar
• Ma, ES., Zheng, B.G. and Yu, R.X. (1983) "Observation of the therapeutic effect of sequential application of HOP and HOAP regimen in treating 57 cases of acute Nonlympho-cytic leukemia", Zhejiang Med. J. 5, 17–19.
   Google Scholar
• Hematological Group, Department of Internal Medicine, Affiliated Hospital, Zhejiang Medical Collage (1980) "A report of combined Cephalotaxine ester alkaloids in treatment of 4 cases of acute Promyelocytic leukemia", Zhejiang Med. J. 2, 17–19.
   Google Scholar
• Hua, Z. and Xiong, S.M. (1982) "Clinical traditional drugs to therapeutic effect of combined HOAP and Chinese traditional drugs to acute Nonlymphocytic leukemia", Chin. J. Hematol. 3, 296–298.
   Google Scholar
• Shan, Y.D. (1985) "Analysis of the treatment with HOAP/ HOAGP regimen in 68 cases of acute Nonlymphocytic leukemia", J. Chin. Acad. 65, 590–592.
   Google Scholar
• Lin, B.J. (1986) "Analysis of therapeutic effects and prognostic factors of HOAP chemotherapy regimen of acute Nonlymphocytic leukemia", Chin. J. Hematol. 7, 5–8.
   Google Scholar
• Lin, M.F. (1986) "Preliminary study on HAT of HCT regimen of acute Nonlymphocytic leukemia", Chin. J. Hematol. 7, 9–10.
   Google Scholar
• Zhao, Y.P., Bian, SG. and Meng, Q.X. (1995) "Homo-harringtonine, Cytarabine and Daunorubin (HAD) combination chemotherapy for adult acute myeloid leuke-mia (ANLL)", Chin. J. Hematol. 16, 59–61.
   Google Scholar
• Yao, Y.H. (1999) "Comparison of therapeutic effect of HA and DA protocol in adult acute Nonlymphocytic leukemia", Acta Acad. Med. Xuzhou. 19, 221–222.
   Google Scholar
• Bian, SG., Hao, YS. and Meng, Q.X. (1990) "Analysis of therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphocytic leukemia", Chin. J. Intern. Med. 29, 22–25.
   PubMedGoogle Scholar
• Zhang, Y.Z., Zhang, Y. and Guo, J.M. (1998) "Homo-harringtonine, Cytarabine and Aclabicin (HAA) combi-nation chemotherapy for acute myeloid leukemia", Chin. J. Clin. Oncol. 25, 758–759.
   Google Scholar
• Feldman, E., Arlin, Z., Ahmed, T., Mittelman, A., Puccio, C., Chun, H., Cook, P. and Baskind, P. (1992) "Homo-harringtonine in combination with cytarabine for patients with acute myelogenous leukemia", Leukemia 6, 1189–1191.
   PubMed Web of Science ®Google Scholar
• Tang, J.Y., Xue, H.L., Pan, C., Chen, J., Gu, L.J. and Zhao, H.J. (2003) "Homoharringtonine based regimen for childhood acute myelogenouse leukemia", Med. Pediatr. Oncol. 41, 70–71.
   PubMedGoogle Scholar
• Zhang, Z.Y., Hou, C.H. and Zhu, YE (1986) "A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine", Chin. J. Intern. Med. 25, 156–157.
   PubMedGoogle Scholar
• Zeng, X.Y., Li, X.S. and Wu, E (1999) "Therapeutic valua of homoharringtonine treatment of CML", Acta Universitatis Medicinalis Secondae Shanghai 19, 406–408.
   Google Scholar
• O'Brien, S., Kantarjian, H., Keating, M., Beran, M., Koller, C., Robertson, L.E., Hester, J., Rios, M.B., Andreeff, M. and Talpaz, M. (1995) "Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase", Blood 86, 3322–3327.
   PubMed Web of Science ®Google Scholar
• Zhang„ TB. (2002) "Clinical study of HHT and LD-ara-C treating chronic myeloid leukemia failing to respond to ]FN-ct treatment", J. Leuk. Lymphoma 11, 292–293.
   Google Scholar
• Kantarjian, H.M., Talpaz, M., Smith, T.L., Cortes, J., Giles, F.J., Rios, MB., Mallard, S., Gajewski, J., Murgo, A., Cheson, B. and O'Brien, S. (2000) "Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia", J. Clin. Oncol. 18, 3513–3521.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., Kantarjian, H., Koller, C., Feldman, E., Beran, M., Andreeff, M., Giralt, S., Cheson, B., Keating, M., Freireich, E., Rios, M.B. and Talpaz, M. (1999) "Sequential homoharring-tonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia", Blood 93,4149–4153.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., Talpaz, M., Cortes, J., Shan, J., Giles, F.J., Faderl, S., Thomas, D., Garcia-Manero, G., Mallard, S., Beth, M., Koller, C., Kornblau, S., Andreeff, M., Murgo, A., Keating, M. and Kantarjian, H.M. (2002) "Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia", Cancer 94,2024–2032.
   PubMed Web of Science ®Google Scholar
• O'Brien, S., Giles, F., Talpaz, M., Cortes, J., Rios, MB., Shan, J., Thomas, D., Andreeff, M., Kornblau, S., Faderl, S., Garcia-Manero, G., White, K., Mallard, S., Freireich, E. and Kantarjian, H.M. (2003) "Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase", Cancer 98, 888–893.
   PubMed Web of Science ®Google Scholar
• Meng, F.Y., Zheng, WY., Liu, X.L., Song, L.L., Xu, B., Zhang, Y. and Huang, E (2003) "Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia", Ai Zheng 22, 840–843.
   PubMedGoogle Scholar
• Kantarjian, H.M., Cortes, J., O'Brien, S., Giles, F.J., Albitar, M., Rios, M.B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D.A., Resta, D. and Talpaz, M. (2002) "Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase", Blood 99, 3547–3553.
   PubMed Web of Science ®Google Scholar
• Ajani, J.A., Dimery, I., Chawla, S.P., Pinnamaneni, K., Benjamin, R.S., Legha, S.S. and Krakoff, I.H. (1986) "Phase 11 studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas", Cancer Treat. Rep. 70, 375–383.
   PubMedGoogle Scholar
• Zhao, T.P., Ding, G.X., Gao, H.Y., Shen, Z.Z. and Li, K.Y. (1986) "A clinical trial of homoharringtonine in the treatment of advanced breast cancer", Tumori 72, 395–402.
   PubMed Web of Science ®Google Scholar
• Runge-Morris, M.A., Kies, M.S., Vokes, E., Blough, R., Weidner, L., Knop, R. and Rowland, K. (1989) "Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase 11 Illinois Cancer Council Study", Invest. New Drugs 7, 269–273.
   PubMed Web of Science ®Google Scholar
• Feun, L.G., Savaraj, N., Landy, H., Levin, H. and Lampidis, T. (1990) "Phase 11 study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors", J. Neurooncol. 9, 159–163.
   PubMed Web of Science ®Google Scholar
• Witte, R.S., Hsieh, P., Elson, E, Oken, MM. and Trump, D.L. (1996) "A phase 11 trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer", Invest. New Drugs 14, 409–413.
   PubMed Web of Science ®Google Scholar
• Witte, R.S., Lipsitz, S., Goodman, T.L., Asbury, RE, Wilding, G., Strnad, CM., Smith, T.J. and Haller, D.G. (1999) "A phase 11 trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer", Invest. New Drugs 17, 173–179.
   PubMed Web of Science ®Google Scholar
• Feldman, E.J., Seiter, K.P., Ahmed, T., Baskind, P. and Arlin, Z.A. (1996) "Homoharringtonine in patients with myelo-dysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia", Leukemia 10, 40–41.
   PubMed Web of Science ®Google Scholar
• Lu, L.H., Lin, S.P. and Liang, Y.Y. (1984) "Clinical study of Cephalotaxus ester in the treatment of polycythemia vera", Chin. J. Intern. Med. 23, 413–415.
   PubMedGoogle Scholar
• Shan, Y.D., Liu, E.K. and Zhang, Z.N. (1985) "Report of treatment with homoharringtonine in polycythemia vera in 13 cases", Beijing Med. J. 7, 262–263.
   Google Scholar